Sage Therapeutics
$88.559876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$88.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$3.89 (-4.21%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell SAGE and other stocks, options, and ETFs commission-free!
About SAGE
Sage Therapeutics, Inc. Common Stock, also called Sage Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA. The listed name for SAGE is Sage Therapeutics, Inc. Common Stock.
CEO
Barry E. Greene
Employees
675
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
5.09B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
528.46K
High Today
$90.73
Low Today
$85.29
Open Price
$89.85
Volume
497.73K
52 Week High
$98.39
52 Week Low
$25.01
Collections
Analyst Ratings
67%
of 21 ratings
Buy
67%
Hold
33%
Sell
0%
SAGE Earnings
-$3.61
-$2.41
-$1.20
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market